GI Innovation FY 2025 Annual ReportBeta
GI Innovation annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
GI Innovation FY 2025 Annual Report Analysis
Business Overview
- • 94.21% of FY2025 revenue from domestic license-out of allergy treatment GI-301, KRW 5,500M recorded for first time
- • GI-301 licensed to Maruho for Japan market, USD 221M deal in Oct 2023, adding regional focus beyond 2020 global Yuhan license
Management Discussion & Analysis
- • Revenue KRW 5.84B (+23,943.8% YoY); operating loss KRW 40.7B (-15.8% YoY); net loss KRW 35.1B (-40.2% YoY)
- • Single business segment: new drug development with KRW 5.5B milestone revenue from GI-301 Phase 2 trial start
Risk Factors
- • USD 10% exchange rate move impacts after-tax profit and capital by ±KRW 13.7B in FY2025, down from ±KRW 56.6B prior year
- • AUD 10% exchange rate move impacts after-tax profit and capital by ±KRW 30.3B in FY2025, newly quantified this year
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding